Vol 20, No 2 (2013)
Original articles
Published online: 2013-04-05

open access

Page views 2841
Article views/downloads 2191
Get Citation

Connect on Social Media

Connect on Social Media

Serum biomarkers and clinical outcomes in heart failure patients treated de novo with carvedilol

Jadwiga Nessler, Bohdan Nessler, Renata Golebiowska-Wiatrak, Ilona Palka, Andrzej Gackowski, Mariusz Kitlinski, Olle Melander, Artur Fedorowski
DOI: 10.5603/CJ.2013.0027
Cardiol J 2013;20(2):144-151.


Background: The role of infl ammatory and hemodynamic stress biomarkers in heart failure
(HF) patients treated de novo with beta-blockers has been poorly studied.

Methods: A total of 86 patients (age 56 ± 9 years, 81 men) with left ventricular ejection fraction
(LVEF) < 40% and previously not treated with beta-blockers were initiated on carvedilol.
At baseline and 12 months later we performed echocardiography, cardiopulmonary exercise
testing, and determined serum levels of B-type natriuretic peptide (BNP), endothelin-1 (ET-1),
C-reactive protein (CRP), interleukin-6, and tumor necrosis factor alpha (TNF -a). Patients
were followed up over a total period of 9 ± 3 years from baseline.

Results: Increased baseline CRP and its on-treatment decrease were associated with improvement
of LVEF (est. coeffi cient per one SD: 1.6; 95% CI: –0.05,3.28; p = 0.056, and –1.80;
–3.43, –0.18; p = 0.030, respectively) and diminishing of LV end-systolic volume index
[mL/m2] (–6.83; –11.32; –2.34; p = 0.003, and 5.85; 1.23; –10.46; p = 0.014, respectively).
Higher baseline ET-1 and on-treatment increase in TNF-a predicted frequent admissions
(> 1) for cardiac complications (odds ratio per one SD: 1.98; 95% CI: 1.09–3.59;
p = 0.025, and 2.07, 1.12–3.84, p = 0.021, respectively) whereas higher baseline BNP was
asociated with increased mortality (hazard ratio per one SD: 2.09, 95% CI: 1.26–3.45;
p = 0.004).

Conclusions: Serum biomarkers may have different roles in prediction of clinical outcomes
among HF patients treated de novo with carvedilol.